New hepatitis b vaccine candidate shows promise in early trial
NCT ID NCT05561673
First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This early-stage study tested a new hepatitis B vaccine that includes an experimental booster called AS37. The goal was to see if the vaccine is safe and triggers a strong immune response. 122 healthy adults aged 18-45 received two doses, and researchers monitored side effects and antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Leuven, 3000, Belgium
-
GSK Investigational Site
Cologne, 51069, Germany
-
GSK Investigational Site
Hamburg, 22143, Germany
-
GSK Investigational Site
Magdeburg, 39120, Germany
-
GSK Investigational Site
Cambridge, CB2 2GG, United Kingdom
Conditions
Explore the condition pages connected to this study.